Atropine is used both to treat a variety of clinical pralidoxime) by military troops facing the threat of disorders and as an antidote to cholinesterase poisoning, nerve gas attack. While various conditions affect the physiologic re-
The pharmacodynamics of atropine sulfate have presponses to atropine, little is known of the pharmacokiviously been studied and its effects on certain physionetics of this drug except under resting conditions. logic responses (heart rate, mydriasis, inhibition of Pharmacokinetic studies were performed in mongrel logi reo (a rat. dogs under two experimental conditions, moderate hemsweating) are known (1-5). orrhage and hypothyroidism, to determine whether im A number of situations alter an individual's physioabsorption and elimination of atropine (0.05 mg/kg body logic responses to atropine. These include: a hot, dry weight) were affected by changes in hemodynamic or climate (2) : prior exercise (2, 6); hypovolemia (7): coadmetabolic status. Using a randomized, crossover experministration of pralidoxime (8); and enclosure in a imental design, it was found that during hypovolemia nuclear, biologic, and chemical (NBC) suit (9). Other the mean volume of distribution was reduced by 22% conditions which, although untested, may influence the (2.50 ± 0.62 vs. 3.21 ± 0.63 L/kgjwith no changes in response to a fixed dose of atropine are: a) extreme peak serum level, total atropine availability, elimination differences in body weight, b) fever, and c) metabolic half-life, or whole-body clearance. Hypothyroidism was disorders. It is not known whether these alterations associated with a significant increase in peak serum reflect differences in drug bioavailability or in altered atropine concentration.(26.4 ± 3.9 vs. 20.6 ± 4.9 ng/ reflec e dv ye ml) and drug bioavailability (48.5 ± 8.8 vs. 30.0 ± 10.7 pha al. ng/ml, h),:while the clearance was reduced by 39%,(426 Because renal excretion normally accounts for the ± 34 vs. 696 ± 187 ng/ml -mini. These results suggest major metabolic clearance of atropine (10, 11), and is that atropine kinetics are not altered appreciably during likely to be depressed during circulatory shock, it is moderate hemorrhage. 4n hypothyroidism, alterations important to determine whether hypovolemia causes in atropine pharmacokinetics may warrant modification increased side-effects from doses of atropine recomof drug dose and frequency of administration. (Crit Care mended for normovolemic individuals. Therefore, we Med 1989; 17:1254) -examined the pharmacokinetics of atropine in both euvolemic and hemorrhagic states. The importance of this study relates to the fact that in conditions utilizing Atropine, an anticholinergic drug, is widely used as chemical warfare agents, atropine would likely be given a preanesthetic medication, for bradycardic syndromes, to patients suffering from acute hemorrhage. A second in the treatment of some ophthalmic disorders, as a objective of this study was to determine whether atrocomponent'of decongestant medications, and as an pine kinetics are influenced by hypothyroidism, a conantidote to certain anticholinesterase toxins. As an dition known to affect the metabolism of numerous antidote, atropine is the treatment of choice for patients drugs (12). affected by chemical warfare nerve agents, and it may be used as a treatment (for self-administration with Smallridge el a/-ATROPINE KINETICS AND HEMORRHAGE 1255 vein to allow for drug administration and was kept Intra-assay and interassay variation coefficients are open by using an infusion (5 ml/h) of 0.9% saline.
MATERIALS AND METHODS

Studies were performed on eight male mongrel dogs
9.0% and 12.8%, respectively. The metabolites tropine Using a randomized crossover design. each dog was and trophic acid do not react with this antibody. studied in both the normovolemic and hypovolemic Serum drug levels were fitted to a multiexponential states with an average rest of 14 days between studies.
function using a modified Marquardt technique for In normovolemic studies, two readings of heart rate nonlinear regression (17). In each instance, the "best (HR) and MAP were obtained over a 30-min baseline fit" model was determined by visual fit of the data to period. Atropine sulfate (0.05 mg/kg body weight im) the various regimen models, and by the most significant was administered in the flank at the end of the baseline r 2 and f ratio. Pharmacokinetic parameters measured period.
included the elimination half-life, volume of distribuIn the hypovolemic study, as in the normovolemic tion (Vd), total clearance, area under the drug timestudy, baseline HR and MAP were obtained twice over concentration curve (AUC), and peak serum atropine 30 min. Animals were then bled (20 ml/kg) into a blood concentration. Differences between treatments were decollection bag over a 60-min period and atropine was termined to be significant at p < .05 by Student's paired administered im 30 min into the bleed. Animals were t-test using the Bonferroni correction for multiple comretransfused (with their shed blood) 1.5 h after atropine parisons (18). administration.
Six animals subsequently underwent surgical thyroid-
RESULTS
ectomy performed under general anesthesia 3 wk before their study. To assure that the animals were hypothyHypo'olemia roid postoperatively, we performed thyrotropin
In normovolemic animals, atropine administration (Thytropar, Armour Pharmaceutical, Kankakee, IL) produced a significant 14% increase in HR ( Table 1) . stimulation tests before and after surgery. Serum thySimilarly, there was a 10% atropine-induced increase roxine (TJ 4 ) concentrations were measured by radioin MAP (p < .05). immunoassay using a kit (Canine T 4 , Diagnostic ProdIn hypovolemic animals, mean maximum HR inucts, Los Angeles, CA) on serum obtained before and creased by 20% and BP increased by 10% during the 6 h after im thyrotropin (10 IU) administration (13).
first 30 min of bleeding before atropine administration Blood samples (2.0 ml each) for atropine measure-( Table 1) . At the time atropine was given, these variments were obtained immediately before, at 2, 3.5, 5, ables had returned to near normal. After atropine ad-7.5. 10, 15. 30, and 45 min, and at 1, 1.25, 1.5, 1.75, ministration, HR increased by 32% and MAP increased 2, 3. 4, 5. and 6 h after atropine administration. BP by 7%. and HR were recorded at each sampling time.
Pharmacokinetic data are illustrated in Table 2 . Serum atropine sulfate concentrations were measThere was a significant decrease in Vd in the hypovolured by radioimmunoassay, similar to that of emic dogs. No other parameter, including peak serum Wurzburger et al. (14), as previously described (15, 16).
concentration, half-life, clearance, or AUC, was signifSensitivity of the assay was 50 pg per tube (1 ng/ml).
icantly affected. 
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IlypothYroidismn ulated that drug-related hypotension (unlike hemorSerum T 4 (mean ± SD) was 2.5 ± 0.9 pg/dl in the rhage) may not impair peripheral tissue perfusion, thus euthyroid dogs, and increased to >6 pg/dl (p < .05) accounting for a lack of effect on atropine metabolism. after thyrotropin in all animals. In the hypothyroid Hypotension was not evident in our study, possibly due state, serum T 4 was 0.3 ± 0.1 g/dl both before and to splenic autotransfusion. The hemodynamic alteraafter thyrotropin.
tions observed suggest a compensatory response with a Hypothyroidism was associated with a significant reduction in circulation to the peripheral vascular bed. reduction in resting rate (Table 1) . While the peak HR The finding of a significant Vd decrease is consistent achieved after atropine was also reduced (171 ± 7 vs. with these observations. Although other parameters 197 ± 7 beat/min), the percentage increase from base-(e.g., half-life) were unaltered, this fact may be due to line was actually greater in the hypothyroid animals. maintenance of BP. From these results, we conclude The MAP was 15% lower basally in the thyroidectothat atropine bioavailability from an im site is not mized animals, but reached levels comparable to the impaired during moderate hemorrhage, provided that euthyroid state after atropine.
BP is maintained. Hypothyroidism was associated with multiple Hypothyroidism may prolong a drug's half-life, prochanges in the kinetic parameters of atropine ( Table 3) . long its clearance, or increase its blood level (12). PosThese changes included a significant reduction in the sible contributing factors include a reduced cardiac drug's clearance, and increases in peak serum concenoutput, renal plasma flow, and hepatic drug metaboliztration ( Fig. 1) and AUC. The mean half-life was proing enzyme activity. Shenfield (12) noted that one longed by 62%. but this change was not statistically cannot predict a priori the effect that thyroid dysfuncsignificant. The Vd was unchanged.
tion might have on a particular drug. There are several reasons for determining the effect of hypothyroidism DISCUSSION on atropine kinetics. First, hypothyroidism occurs more
The current study was designed to examine the effect commonly in elderly patients (2 1) and in association of acute, moderate hemorrhage on atropine sulfate with a bradycardia. Second, patients with hypothyroidabsorption, and elimination from an im site. An earlier ism have undergone successful general surgery and study in cats (7) suggested impaired absorption into the cardiac surgery before treatment with thyroid hormone circulation if atropine was given subcutaneously (blood (22) (23) (24) . Since hospitalized hypothyroid patients might levels were not reported).
therefore receive atropine, either for bradycardia or as In the current experimental model, moderate hema preanesthetic medication, we decided to investigate orrhage led to temporary tachycardia and an increase the effect of hypothyroidism on the drug's metabolism. in MAP. probably through activation of the sympa-
The results of our study indicate that hypothyroidism thetic nervous system (19) and vasoconstriction. delays atropine clearance and increases peak circulating Pihlajamaki et al. (20) demonstrated that sodium blood levels. These experimental observations suggest nitroprusside-induced hypotension in anesthetized man that both the dose and frequency of atropine adminisdoes not impair im absorption of atropine. They spectration should be modified in clinical hypothyroidism. T,,,, elimination half-life, clearance, total body drug clearance; peak conc, peak serum atropine level. Numbers in parentheses indicate range. a p < .05. 
